Page 46 - Diamicron MR MIG Cycle 2(20-21) Final

Visual Aids Page 4
Diamicron MR 60 (Metformin Uncontrolled Patients)

Page 4: Very Low Risk of Hypoglycemia:

Moreover, with Diamicron MR 60 you can provide such excellent efficacy without compromising patients’
safety.

In diabetes patients on fasting who has very high risk for hypoglycemia, you can find that rate of hypoglycemia
is very less (2.2%) with Diamicron MR 60 even count on symptomatic episodes. But in your patients at daily
practice, Diamicron MR 60 has very low rate (0.3%) of symptomatic hypoglycemia

By choosing Diamicron MR 60, you can regain your control at 7% from the 1st day with no compromise on safety.

Objective

To convince the doctors that Diamicron MR 60 has very low rate of Hypoglycemia even in fasting
patients who have very high risk for Hypoglycemia and patients at daily clinical practice.

Comments
Diamicron MR provide excellent efficacy together with remarkable safety and it is very important to
differentiate Diamicron MR from other OADs.

DIA-RAMANDAN
Key End Points

 Primary End points: Proportion of patients with at least 1 symptomatic hypoglycemic event.
 Secondary End points
1. Change of HbA1c level, fasting plasma glucose (FPG), and weight between inclusion and end
of the study
2. Proportion of patients with at least 1 confirmed hypoglycemia event
3. Proportion of patients with at least 1 severe hypoglycemia event
Methodology
DIA-RAMADAN was a real-world, prospective, international, multicenter study including adult
patients with T2D with controlled or suboptimally controlled HbA1C (<9%), who were already
undergoing treatment with breakable gliclazide MR 60 mg for at least 90 days before the start of
the study , and not requiring insulin treatment (Figure 1). Participants continued their T2D
treatment according to usual practice and doctor’s recommendations. A patient diary was provided
at the beginning of the study for collecting hypoglycemia and adverse events. All data was collected
in eCRF and regularly monitoring during study.